Nuwellis is a commercial-stage fluid-management company trying to prove that Aquadex ultrafiltration can become a recurring hospital franchise before the capital structure consumes the residual claim. Mike McCormick took the chief executive role at the end of June after John Erb stepped down from day-to-day leadership while remaining chairman. The second-quarter print shows the commercial story is no longer just a reset narrative. United States circuit and console demand lifted sales, and the installed base expanded enough to make utilization the real test rather than another placement headline.
Gross margin jumped to 76 percent from the mid-fifties a year earlier after the shift of production to KDI Manufacturing and last year's price reset. That is a real operating change, not a one-quarter mix accident. The offset is that selling and development spending still outruns the revenue base, so the company remains a cash consumer even as the product economics improve. Management now points to roughly $9 million of cash after the summer financings and describes runway into late next year, yet the mid-year statements still carry substantial-doubt language.
Nine consoles went out in the June quarter versus three a year earlier, and first-half placements reached two dozen against five. Pediatrics, intensive-care programs, and heart failure all grew at high-twenties rates in the first half. The investment debate is whether circuit pull-through on that larger installed base can shrink the cash gap before another reverse split or registered direct becomes the next chapter. Does utilization compound, or does the warrant stack and the Nasdaq equity test keep the residual claim in a permanent recapitalization cycle?